We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress
Sign In
Advertise with Us
GENRUI BIOTECH INC.

CHEMBIO DIAGNOSTIC SYSTEMS

Chembio develops, manufactures and commercializes diagnostic solutions and products for the rapid and early detection... read more Featured Products: More products

Download Mobile App





Chembio Launches Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B from Single Patient Sample in 15 Minutes

By LabMedica International staff writers
Posted on 07 Apr 2021
Print article
Illustration: Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B (Photo courtesy of Chembio Diagnostic Systems, Inc.)
Illustration: Rapid POC Test for Detecting COVID-19 Antigens, Flu A/B (Photo courtesy of Chembio Diagnostic Systems, Inc.)
Chembio Diagnostic Systems, Inc. (Medford, NY, USA) has commercially launched an FDA Emergency Use Authorization-approved, in-licensed rapid point-of-care COVID-19/Flu A&B test, for use in decentralized and traditional testing settings.

The rapid immunoassay test is approved for use in laboratories with a CLIA waiver license, produces results in 15 minutes and requires no instrumentation. The test simultaneously differentiates SARS-CoV-2 antigens and influenza Type A and Type B infections from a single swab.

“As COVID-19 converges with the flu, it is critical for physicians to be able to quickly differentiate between these viruses at the point-of-care, which present with nearly identical symptoms, in order to take appropriate clinical actions and maximize efficient use of healthcare resources,” said Charles Caso, Vice President of Sales and Marketing for Chembio. “Based on recent research, we expect that the spread of COVID-19 will eventually transition from a pandemic to an endemic state, with the virus surviving among the population at a lower incidence. In this scenario, coupled with the return to normalcy in society, we see COVID-19 testing remaining a crucial and integral component of broader respiratory testing.”

Gold Supplier
SARS-CoV-2 (COVID-19) Antibody Test
INgezim COVID 19 CROM
New
Silver Supplier
COVID-19 Ag Rapid Test
COVID-19 Ag Rapid Test Kit
SARS-CoV-2 Antigen Test
ESPLINE SARS-CoV-2 Antigen Test
Gold Supplier
COVID-19 Test
ID NOW COVID-19

Print article
BIOHIT  Healthcare OY

Channels

Molecular Diagnostics

view channel
Image: Representation of the molecular structure of the cathepsin B (catB) protein (Photo courtesy of Wikimedia Commons)

An Ultrasensitive Assay for Measurement of Levels of Cathepsin B in the Blood

A novel digital enzyme-linked immunosorbent assay (ELISA) has been developed for the differential detection of cathepsin B from samples of serum or plasma. Cathepsin B (catB) is a lysosomal cysteine... Read more

Industry

view channel
Illustration

Global Digital PCR and Real-Time PCR Market Growth Driven by Increasing Cases of Infectious Diseases

Increasing cases of infectious diseases, rising geriatric population and growing number of genetic disorders will propel the growth of the global digital PCR and real-time PCR market over the next decade.... Read more
Copyright © 2000-2021 Globetech Media. All rights reserved.